Sportizumab – Multimodal progressive exercise over 10 weeks decreases Th17 frequency and CD49d expression on CD8+ T cells in relapsing-remitting multiple sclerosis: A randomized controlled trial
S. Proschinger, S. Belen, F. Adammek, M.L. Schlagheck, A. Rademacher, A. Schenk, C. Warnke, W. Bloch, P. Zimmer, Brain, Behavior, and Immunity 124 (2024) 397–408.
Download
No fulltext has been uploaded.
Journal Article
| Published
| English
Author
Proschinger, Sebastian;
Belen, Sergen;
Adammek, Frederike;
Schlagheck, Marit LeaLibreCat 
;
Rademacher, Annette;
Schenk, Alexander;
Warnke, Clemens;
Bloch, Wilhelm;
Zimmer, Philipp
;
Rademacher, Annette;
Schenk, Alexander;
Warnke, Clemens;
Bloch, Wilhelm;
Zimmer, PhilippPublishing Year
Journal Title
Brain, Behavior, and Immunity
Volume
124
Page
397-408
ISSN
LibreCat-ID
Cite this
Proschinger S, Belen S, Adammek F, et al. Sportizumab – Multimodal progressive exercise over 10 weeks decreases Th17 frequency and CD49d expression on CD8+ T cells in relapsing-remitting multiple sclerosis: A randomized controlled trial. Brain, Behavior, and Immunity. 2024;124:397-408. doi:10.1016/j.bbi.2024.12.017
Proschinger, S., Belen, S., Adammek, F., Schlagheck, M. L., Rademacher, A., Schenk, A., Warnke, C., Bloch, W., & Zimmer, P. (2024). Sportizumab – Multimodal progressive exercise over 10 weeks decreases Th17 frequency and CD49d expression on CD8+ T cells in relapsing-remitting multiple sclerosis: A randomized controlled trial. Brain, Behavior, and Immunity, 124, 397–408. https://doi.org/10.1016/j.bbi.2024.12.017
@article{Proschinger_Belen_Adammek_Schlagheck_Rademacher_Schenk_Warnke_Bloch_Zimmer_2024, title={Sportizumab – Multimodal progressive exercise over 10 weeks decreases Th17 frequency and CD49d expression on CD8+ T cells in relapsing-remitting multiple sclerosis: A randomized controlled trial}, volume={124}, DOI={10.1016/j.bbi.2024.12.017}, journal={Brain, Behavior, and Immunity}, publisher={Elsevier BV}, author={Proschinger, Sebastian and Belen, Sergen and Adammek, Frederike and Schlagheck, Marit Lea and Rademacher, Annette and Schenk, Alexander and Warnke, Clemens and Bloch, Wilhelm and Zimmer, Philipp}, year={2024}, pages={397–408} }
Proschinger, Sebastian, Sergen Belen, Frederike Adammek, Marit Lea Schlagheck, Annette Rademacher, Alexander Schenk, Clemens Warnke, Wilhelm Bloch, and Philipp Zimmer. “Sportizumab – Multimodal Progressive Exercise over 10 Weeks Decreases Th17 Frequency and CD49d Expression on CD8+ T Cells in Relapsing-Remitting Multiple Sclerosis: A Randomized Controlled Trial.” Brain, Behavior, and Immunity 124 (2024): 397–408. https://doi.org/10.1016/j.bbi.2024.12.017.
S. Proschinger et al., “Sportizumab – Multimodal progressive exercise over 10 weeks decreases Th17 frequency and CD49d expression on CD8+ T cells in relapsing-remitting multiple sclerosis: A randomized controlled trial,” Brain, Behavior, and Immunity, vol. 124, pp. 397–408, 2024, doi: 10.1016/j.bbi.2024.12.017.
Proschinger, Sebastian, et al. “Sportizumab – Multimodal Progressive Exercise over 10 Weeks Decreases Th17 Frequency and CD49d Expression on CD8+ T Cells in Relapsing-Remitting Multiple Sclerosis: A Randomized Controlled Trial.” Brain, Behavior, and Immunity, vol. 124, Elsevier BV, 2024, pp. 397–408, doi:10.1016/j.bbi.2024.12.017.
Google Scholar